2026 | Evolve | VBS | Fellows Foray

Clinical Practice Snapshot

As part of this year’s VBS submission process, we are collecting brief insights into how fellows approach common decision points in patient care. Your responses will be aggregated anonymously and help inform future educational initiatives. Please answer all questions based on your own clinical perspective.

This has no impact on video scoring or finalist selection.

What is the longest real-world treatment interval you are comfortable extending to in patients with nAMD, with a second-generation anti-VEGF agent?*

In patients demonstrating an inadequate response to initial monthly medical therapy for DME, how quickly do you typically escalate care (e.g., switch therapy or add steroid)?*

After 1-2 injectionsAfter 3-4 injectionsAfter 5-6 injectionsAs long as there is continued improvement, would not escalate care

In patients with DME, which statements best reflect your approach to treatment extension in the presence of residual fluid after loading with a second-generation agent? (Select up to 3)*

I tolerate some fluid (i.e., stable SRF) if the anatomy is otherwise stable and vision is goodI may tolerate a small amount of IRF, if vision is unaffectedI only extend if the fluid is resolving or improvingI require resolution of all foveal fluid before extendingI do not extend in the presence of any fluidI generally follow the trial protocols for the agent in questionOther (Please Specify)

Assuming a patient would benefit from a second-generation agent for retinal diseases, which factors most influence your choice or ability to initiate treatment? (Select up to 3)*

Clinical trial efficacy dataLong-term or real-world dataPersonal experience or clinical confidenceInstitutional formulary access or stocking availabilityInsurance or prior authorization requirementsGuidance from a senior colleague or partnerOther (Please Specify)

What are the most challenging parts of counseling a patient starting chronic intravitreal therapy? (Select up to 3)*

Explaining the need for ongoing/frequent treatmentAddressing patient fears about injectionsManaging unrealistic expectations (e.g., vision improvement vs. stability)Discussing long-term outcomes or uncertaintiesEncouraging adherence despite lack of immediate resultsBalancing clinical recommendations with patient lifestyle/preferencesNone – I don’t find these conversations particularly challengingOther (Please Specify)

Name*

First NameLast Name

NPI Number

Email*

example@example.com

Institution*

Address*

Street Address

Street Address Line 2

CityState / Province

Postal / Zip CodeCountry

File Details / Instructions / Description*

Is there anything you'd like us to know about your video? If not, list NA

File Upload*

.mp4, .mov file types allowed. Max file size is 1 GB.

In consideration of my participation in the Vit-Buckle Society (VBS) Fellows Foray scheduled April 9, 2026 (herein the “Meeting”), I hereby grant US HealthConnect, Inc. and its subsidiaries, and VBS (herein the “Parties”) (i) the right to make an audio and/or video recording of my presentation and/or to reproduce my presentation material (such as slides, audio visual materials, or papers) to create a full record of my presentation (the “Presentation") and (ii) a fully paid, royalty free, global, non-exclusive license to use the Presentation for any legal purpose expressly including posting to social media platforms.

I Accept*

Yes

Signature*